Page 16 - வெர்டெக்ஸ் மருந்துகள் இணைக்கப்பட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results February 1, 2021 GMT BOSTON (BUSINESS WIRE) Feb 1, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provided full-year 2021 financial guidance. “Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple combination in the U.S. and the EU. It was also a year marked by meaningful pipeline advancement. We now have clinical programs in seven disease areas, spanning multiple modalities including small molecules for alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases, gene editing for sickle cell disease and beta thalassemia, and cell therapy for type 1 diabetes,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Verte

United statesReshma kewalramaniSwiss agency for therapeutic productsEuropean commissionDrug administrationHealth canadaVertex pharmaceuticals incorporated nasdaqVertex pharmaceuticals incorporatedPharmaceuticals incorporatedChief executive officerMonths ended decemberIncome taxSwiss agencyTherapeutic productsNew drug applicationPriority review